Canaccord analyst Mark Massaro raised his price target for Exact Sciences (EXAS) to $110 from $100 and maintained a Buy rating after the company's Q1 beat and guide for Q2 revenue and volumes above consensus. In a research note to investors, Massaro says he is "impressed" at the strong demand that the joint Pfizer (PFE) and Exact reps are stirring up in the field, coupled with refinements both are making to maximize its impact. Exact seems to be getting better and better and remains among the elite growth companies in Massaro's sector, adding that Exact remains one of his top picks for 2019. He views 2019 raised guidance as beatable, which sets the stock up for further gains this year.